Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals... Show more
SBFM saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 28, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on November 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SBFM as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
SBFM moved below its 50-day moving average on November 14, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for SBFM crossed bearishly below the 50-day moving average on November 19, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SBFM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for SBFM entered a downward trend on November 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SBFM advanced for three days, in of 189 cases, the price rose further within the following month. The odds of a continued upward trend are .
SBFM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.280) is normal, around the industry mean (17.139). P/E Ratio (0.260) is within average values for comparable stocks, (72.460). SBFM's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.930). SBFM has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (0.129) is also within normal values, averaging (52.518).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. SBFM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SBFM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry PharmaceuticalsGeneric
A.I.dvisor tells us that SBFM and OGI have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and OGI's prices will move in lockstep.
| Ticker / NAME | Correlation To SBFM | 1D Price Change % | ||
|---|---|---|---|---|
| SBFM | 100% | -0.72% | ||
| OGI - SBFM | 25% Poorly correlated | +1.37% | ||
| NBIX - SBFM | 25% Poorly correlated | +2.02% | ||
| AMRX - SBFM | 24% Poorly correlated | +3.78% | ||
| ELAN - SBFM | 24% Poorly correlated | +4.76% | ||
| RMTI - SBFM | 23% Poorly correlated | +4.24% | ||
More | ||||
| Ticker / NAME | Correlation To SBFM | 1D Price Change % |
|---|---|---|
| SBFM | 100% | -0.72% |
| Pharmaceuticals: Generic industry (214 stocks) | 30% Poorly correlated | +1.55% |